Welcome Address
A. Kotsakis (GR), N. Karachaliou (DE)
Chairs: G. Koukoulis (GR), N. Karachaliou (DE)
08.30-08.50 Microenvironment in NSCLC P. Foukas (GR)
08.50-09.10 Heterogeneity of NSCLC and tumor evolution C. Hiley (UK)
09.10-09.20 Q&A
Ο1-1 09.20 -09.35 AN INTERTWINED LYSOSOMAL GENE EXPRESSION AND FUNCTION MODULE DRIVEN BY TYPE I IFNS SHAPES CDCS1 IN TUMORS
E. Aerakis, D. Kerdidani, I. Angelidis, M. Matthaiakaki, S. Henri, M. Tsoumakidou
Ο1-2 09.35-09.50 HLA-CLASS-I EXPRESSION IS FREQUENTLY LOST IN NSCLC AND RELATES WITH
LOW CD8+ LYMPHOCYTIC INFILTRATION AND POOR POSTOPERATIVE PROGNOSIS
A. Giatromanolaki, I. M. Koukourakis, M. Kouroupi, M. I. Koukourakis
Ο1-3 09.50-10.05 THE ROLE OF PATIENT-DERIVED XENOGRAFTS IN INTRATUMOR HETEROGENEITY STUDIES
Z. Kanaki, A. Voutsina, A. Markou, I.S. Pateras, K. Potaris, M. Avgeris, P. Makrythanasis, E. Athanasiadis, I. Vamvakaris, E. Patsea, K. Vaclav, E. Lianidou, V. Georgoulias, A. Kotsakis, A. Klinakis
Chairs: A. Kotsakis (GR), D. Papadatos - Pastos (UK)
10.05-10.25 Challenges in Covid-19 era in the treatment of thoracic Tumors G. Geropoulos (UK)
10.25-10.30 Q&A
Coffee Break
Chairs: P. Christopoulos (DE), F. Ι. Dimitrakopoulos (GR)
11.00-11.20 Rare EGFR mutations: How to treat? A. Georgiou (UK)
11.20-11.40 The future of TKIs in the adjuvant setting E. Karapanagiotou (UK)
11.40-12.00 Targeting resistance mechanisms to EGFR TKIs I. Mountzios (GR)
12.00-12.10 Q&A
Ο2-1 12.10-12.25 DETECTION OF EGFR MUTATIONS IN PLASMA cfDNA AND PAIRED CTCs OF NSCLC PATIENTS BEFORE AND AFTER OSIMERTINIB THERAPY USING CRYSTAL DIGITAL PCR
A. Ntzifa, A. Kotsakis, V. Georgoulias, E. Lianidou
O2-2 12.25-12.40 IDENTIFICATION OF PD-L1 AND pS6 EXPRESSION IN CIRCULATING TUMOR CELLS OF OSIMERTINIB-TREATED NON-SMALL-CELL LUNG CANCER PATIENTS
E. Pantazaka, Α. Ntzifa, E. Lianidou, A. Kotsakis, V. Georgoulia, G. Kallergi
Chairs: G. Oikonomopoulos (GR), E. Karapanagiotou (UK)
12.40-13.00 ALK positive lung cancer P. Christopoulos (DE)
13.00-13.20 KRAS mutant lung cancer: light at the end of the tunnel? F. Koinis (GR)
13.20-13.30 Q&A
Light lunch
Chairs: P. Christopoulos (DE), Ch. Charalambous (CY)
14.00-14.20 Diagnosis and treatment of MET-positive NSCLC N. Karachaliou (DE)
Sponsored by Merck
14.20-14.40 Diagnosis and treatment of ΗΕR2-positive NSCLC G. Nintos (UK)
14.40-15.00 Diagnostic workup and treatment of NTKR positive tumors M. Rovithi (GR)
15.00-15.20 The future of ADCs in advanced NSCLC K. Boleti (UK)
15.20-15.35 Q&A
Ο3-1 15.35-15.50 ACTIVITY OF OSIMETRINIB IN PRETREATED PATIENTS (pts) WITH EPIDERMAL RECEPTOR GROWTH FACTOR MUTANT (EGFRmt) NON-SMALL CELL LUNG CANCER (NSCLC), ACCORDING TO DETECTION OF CIRCULATING PLASMA DNA (ctDNA)
E. Kontopodis, G. Kallergi, A. Ntzifa, N. Jordana-Ariza, N. Karachaliou, E. Pantazaka,
Ch. Charalambous, A. Psyrri, A. Tsaroucha, I. Boukovinas, A. Koumarianou, D. Hatzidaki,
E. Lianidou, V. Georgoulias, R. Rosell, A. Kotsakis
Ο3-2 15.50-16.05 IS VIDEO-ASSISTED THORACOSCOPIC (VATS) SLEEVE LOBECTOMY A FEASIBLE ALTENATIVE TO OPEN SURGERY FOR CENTRALLY LOCATED NON-SMALL CELL LUNG CANCER?
I. Loufopoulos, G. Geropoulos, N. Madouros, K. Kapriniotis,
C. Kakos, Κ. Bhakhri, D. Papadatos - Pastos, N. Panagiotopoulos
Coffee Break
Chairs: Κ. Boleti (UK), F. I. Dimitrakopoulos (GR)
16.30-16.50 Monitoring of minimal residual disease using ctDNA C. Abbosh (UK)
16.50-17.10 Monitoring of metastatic disease with ctDNA F. Papageorgiou (GR)
17.10-17.30 Liquid Biopsy Biomarkers in Lung Cancer E. Lianidou (GR)
17.30-17.40 Q&A
Ο4-1 17.40-17.55 EVALUATION OF MONOCARBOXYLATE TRANSPORTER 4 (MCT4) EXPRESSION AND
ITS PROGNOSTIC SIGNIFICANCE IN CIRCULATING TUMOR CELLS FROM PATIENTS WITH EARLY STAGE NON-SMALL-CELL LUNG CANCER
Α. Markou, E. Tzanikou, G. Kallergi, E. Pantazaka, V. Georgoulias, A. Kotsakis, E. Lianidou
Ο4-2 17.55-18.10 DNA METHYLATION ANALYSIS OF SELECTED TUMOR SUPPRESSOR GENES IN CIRCULATING TUMOR CELLS AND PAIRED PLASMA SAMPLES OF EARLY STAGE NSCLC PATIENTS
Τ. Lontra, V. Tserpeli, Α. Kotsakis, V. Georgoulias, Ε. Lianidou, Α. Markou
Chairs: D. Papachristou (GR), A. Klinakis (GR)
18.10-18.35 Molecular Pathology of Lung Cancer K. Linos (US)
18.35-18.40 Q&A
18.40-19.05 Incorporating functional genomics in the treatment of NSCLC G. Vasmatzis (US)
19.05-19.10 Q&A
19.10-19.35 New therapies in 1L metastatic NSCLC: how confident we are? G. Fotopoulos (CY)
Sponsored by Bristol Myers Squibb
19.35-19.45 Q&A
Chairs: M. Tsoumakidou (GR), Κ. Κosmatopoulos (FR)
08.45-09.05 TILs as a valid biomarker for immunotherapy I. Pateras (GR)
09.05-09.25 Immunology of new targeted therapies and immune checkpoint inhibitors P. Verginis (GR)
09.25-09.45 Novel approaches in Clinical practice D. Papadatos - Pastos (UK)
09.45-09.55 Q&A
Ο5-1 09.55-10.05 T-CELL RECEPTOR REPERTOIRE PROFILING OF METASTATIC NON-SMALL-CELL LUNG CANCER WITH HIGH PD-L1 EXPRESSION
M. Elshiaty, F. Lusky, H. Sültmann, A. Stenzinger, M. Thomas, P. Christopoulos
O5-2 10.05-10.20 CLINICAL ACTIVITY OF AN hTERT-SPECIFIC CANCER VACCINE (Vx-001) IN
“IMMUNE DESERT” NSCLC
I. S. Pateras, A. Kotsakis, M. Avgeris, E. Baliou, P. Kouroupakis, E. Patsea, V. Georgoulias,
J. Menez-Jamet, J-P. Kinet, K. Kosmatopoulos
O5-3 10.20-10.35 A CROSS-TALK BETWEEN CANCER ASSOCIATED FIBROBLASTS (CAFs) AND
T REGULATORY CELLS (Tregs) PROMOTES SUPPRESSION OF THE ANTI-TUMOR IMMUNITY AND BOLSTERS TUMOR DEVELOPMENT
A. Varveri, M. Papadopoulou, A. Delis, P. Foukas, P. Verginis
Coffee Break
Chairs: V. Georgoulias (GR), K. Belessiotis (UK)
11.00-11.20 The perspectives of immunotherapy in the curative setting N. Pistamaltzian (GR)
Sponsored by Roche
11.20-11.40 Update of immunotherapy for advanced oncogene driven NSCLC D. Papadatos - Pastos (UK)
11.40-12.00 Update of immunotherapy for advanced non-oncogene driven NSCLC G. Oikonomopoulos (GR)
12.00-12.10 Q&A
O6-1 12.10-12.25 ULTRA-HYPOFRACTIONATED RE-IRRADIATION WITH anti-PD-1 IMMUNOTHERAPY FOR STAGE III RECURRENT NON-SMALL CELL LUNG CARCINOMA (NSCLC)
I. M. Koukourakis, A. Giaktzidis, P. Mamalis, A. Giatromanolaki, M. I. Koukourakis
O6-2 12.25-12.40 HYPOXIA ENHANCES PD-L1 AND CD47 IMMUNE CHECKPOINT MOLECULES IN
LUNG CANCER CELL-LINES
A. Mitrakas, A. Giatromanolaki, M. I. Koukourakis
Chairs: N. Pistamaltzian (GR), S. Baka (GR)
12.40-13.00 Immunotherapy in special populations D. Ziogas (GR)
13.00-13.20 Therapeutic options after immunotherapy failure Ch. Charalambous (CY)
13.20-13.30 Q&A
Light Lunch
Chairs: M. Koukourakis (GR), G. Ioannidis (CY)
14.00-14.20 Molecular profiling in SCLC F. I. Dimitrakopoulos (GR)
14.20-14.40 Immunotherapy treatment in SCLC: Meeting the expectations V. Sarris (GR)
Sponsored by Astra Zeneca
14.40-15.00 New targets and future directions in SCLC K. Leventakos (USA)
15.00-15.10 Q&A
Chairs: Μ. Rovithi (GR), G. Fotopoulos (CY)
15.10-15.30 Molecular Biomarkers in Mesothelioma D. Oluf Roe (NOR)
15.30-15.50 The emerging therapeutic landscape in mesothelioma I. Metaxas (SUI)
15.50-16.10 Implementation of targeted therapies and immunotherapy in the treatment
of thymic malignancies S. Gennatas (UK)
16.10-16.20 Q&A
Coffee Break
Chairs: A. Giatromanolaki (GR), N. Karachaliou (DE)
17.00-17.30 Molecular Landscape of Response to Immune Checkpoint Blockade in Lung Cancer:
Nuances, Challenges and Clinical Utility V. Anagnostou (USA)
17.30-18.00 KRAS and Immunotherapy F. Skoulidis (USA)
Chairs: T. Diamantopoulos (UK), M. Koukourakis (GR), D. Papadatos - Pastos (UK),
N. Panagiotopoulos (UK), A. Giatromanolaki (GR)
18.00-18.10 Patient with stage III NSCLC K. Belessiotis (UK)
18.10-18.20 Discussion Tumor Board
18.20-18.30 Patient with oligo-metastatic NSCLC Α. Kokkalis (GR)
18.30-18.40 Discussion Tumor Board
18.40-18.50 Patient with oligo-progressive NSCLC A. Markou (GR)
18.50-19.00 Discussion Tumor Board
Chairs: P. Kosmidis (GR), Α. Κοtsakis (GR)
Immunotherapy with bispecific antibodies N. Karachaliou (DE)
Closing Remarks
